Ketoacidosis

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Lithium, UGT, Risk, Digoxin, Shanda, Hypotension, FDA, SGLT1, Type 2 diabetes, Acute kidney injury, Congress, Pyelonephritis, Conference, Fever, Ketoacidosis, Pregabalin, Pregnancy, Pain, Assessment, Gabapentin, Tenderness, New Drug Application, Amber Grid, HCM, Common, SGLT2, PROGRESS, Hypertrophic cardiomyopathy, Diabetes, Kidney, Heart failure, Dialysis, History, Patient, Prescription, Type, Neuropathic pain, Webcast, Insulin, T2DM, EGFR, Erythema, T1DM, Hypoglycemia, Partnership, Contraindication, Diarrhea, NDA, Incidence, Swelling, Urinary tract infection, Hospital, Chronic kidney disease, Internationalized domain name, Metabolic acidosis, Creatinine, Growth, Lactation, Pharmaceutical industry

THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.

Key Points: 
  • THE WOODLANDS, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives, today announced a business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-12, 2024.
  • “Lexicon achieved major advancements in 2023 in its business and pipeline of pharmaceutical innovations,” said Lonnel Coats, chief executive officer and director of Lexicon.
  • The company will also focus on ensuring a strong ongoing awareness of INPEFA in the medical community through medical publications and congress presence.
  • Company to Present at J.P. Morgan Healthcare Conference Thursday, January 11, 2024 at 10:30am PST (1:30pm ET)
    Lonnel Coats, Lexicon’s chief executive officer, will make a company presentation.

American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹

Retrieved on: 
Thursday, October 19, 2023
Cardiac arrest, ECG, Injection, Seizure, Arrhythmia, Nephrocalcinosis, Hypercalcaemia, Infant, Kidney, Continuity, Risk, Hyperkalemia, Death, Parenteral nutrition, Child, Potassium, Lactation, Thrombosis, Acute kidney injury, Milk, Tetany, Toxicity, Phosphate, Patient, Central nervous system, Bolus, Hyperphosphatemia, Hypophosphatemia, Hypotension, Hypocalcemia, Tubing (recreation), Pulmonary embolism, Use, Aluminium, Administration, Late preterm infant, QT, Calcium, Ketoacidosis, Phosphorus, Birth control, Medical device, Pharmaceutical industry, Magnesium deficiency

In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.

Key Points: 
  • In addition, inappropriate intravenous administration of undiluted or insufficiently diluted potassium phosphates as a rapid "IV push" has resulted in cardiac arrest, cardiac arrhythmias, hypotension, and death.
  • Vein Damage and Thrombosis: Potassium Phosphates Injection must be diluted and administered in intravenous fluids or used as an admixture in parenteral nutrition.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes

Retrieved on: 
Thursday, August 17, 2023
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Data Management, Health Technology, Technology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Glycosuria, Dialysis, Gangrene, Pain, Urinary tract infection, 1946 Antarctica PBM Mariner crash, Incidence, Patient, Risk, PBM, Insulin, Ulcer, Pancreatitis, Diet, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, World Market (store), Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Erythema, Swelling, Type, Moyamoya disease, Knee, Infection, Pyelonephritis, Elijah Cummings Lower Drug Costs Now Act, Partnership, Hospital, Necrotizing fasciitis, Diabetic ketoacidosis, Pharmacy, Perineum, SGLT2, Ketoacidosis, Acute kidney injury, Frenz, Nausea, Female, Pharmaceutical industry, Dietary supplement, Medical imaging, Meat

Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.

Key Points: 
  • Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
  • BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Diabetes is the most expensive chronic condition in the U.S. and accounts for 1 of every 4 dollars spent on healthcare.
  • In patients with type 1 diabetes mellitus, BRENZAVVY significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate.

TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

Retrieved on: 
Thursday, July 13, 2023
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Dialysis, Gangrene, Pain, Urinary tract infection, A1C, Incidence, Patient, Risk, Insulin, Ulcer, Fasting, Pancreatitis, Diet, Urine, PBC, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, DPP4, Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, EGFR, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Blood, Erythema, Metformin, Swelling, Type, Moyamoya disease, Knee, Blood pressure, Medicine, Infection, Pyelonephritis, Food, Hospital, Fatal, Necrotizing fasciitis, Glomerular filtration rate, Diabetic ketoacidosis, Perineum, Calorie, SGLT2, Ketoacidosis, Acute kidney injury, Nausea, Bexagliflozin, Female, Pharmaceutical industry, Dietary supplement, Meat

BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.

Key Points: 
  • BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.
  • BRENZAVVY treatment can be initiated in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2.
  • "We are excited to offer Brenzavvy to our patients with diabetes," said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company.
  • "TheracosBio is breaking new ground by making this product available to consumers at a transparent, low price.

Stars Unite on Capitol Hill to Fight Type 1 Diabetes With JDRF

Retrieved on: 
Thursday, June 22, 2023
ESPN, JDRF, NFL, Insulin, International, Senior, 2020 BBC Sports Personality of the Year Award, SDP, Pancreas, Hope, Marriott Marquis, Research, Ketoacidosis, Bangladesh Technical Education Board, Congress, Super Bowl, Sport, Teplizumab, Washington Marriott Marquis, Family, Disease, Entertainment, Pharmaceutical industry, Music, T1D

WASHINGTON, June 22, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce the 2023 JDRF Children's Congress, a three-day Washington D.C event that will bring children living with T1D face-to-face with lawmakers and top decision-makers. Youth delegates from across the country, as well as JDRF's five international affiliates, will be joined by celebrity advocates to call on congress to renew the Special Diabetes Program (SDP) and advocate for policies to ensure insulin is available at an affordable and predictable price.

Key Points: 
  • The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health.
  • "The Special Diabetes Program has supported critical research that has moved us closer than ever to new treatments for type 1 diabetes and its complications and ultimately cures," said Aaron Kowalski, Ph.D., JDRF CEO.
  • JDRF is particularly grateful to our celebrity advocates for adding their voices to this fight.
  • Their influence and personal experiences are invaluable in raising awareness about type 1 diabetes and the critical need to further research."

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

Retrieved on: 
Saturday, June 3, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Solar eclipse of May 1, 1185, Neutropenia, Pancreatic cancer, Capecitabine, RECIST, Toxicity, Appetite, ASCO, Death, Sarcoma, Ketoacidosis, American Society of Clinical Oncology, Poster, Patient, Anemia, MCT, Monocarboxylate transporter 8, Nausea, Toxic leukoencephalopathy, Ovarian cancer, Therapy, Society, Safety, Fatigue, Pharmaceutical industry, Vaccine, Medical imaging, MD

Key secondary objectives include evaluation of safety and tolerability, determination of the pharmacokinetic parameters, optimal dosing regimen for each combination and characterization of preliminary anti-tumor activity of the combinations.

Key Points: 
  • Key secondary objectives include evaluation of safety and tolerability, determination of the pharmacokinetic parameters, optimal dosing regimen for each combination and characterization of preliminary anti-tumor activity of the combinations.
  • The data presented in the poster are the first report of preliminary results of an ongoing study.
  • Fourteen patients in the capecitabine arm were response evaluable and eight patients in the gemcitabine arm were response evaluable.
  • The dose escalation of CYT-0851 in combination with gemcitabine is ongoing and the study has cleared the 200 mg dose.

Out of Control: U.S. Employers Spend $245B a Year on Diabetes as Diagnosis Rates Rise, New Nomi Health Data Shows

Retrieved on: 
Tuesday, March 14, 2023
Medical Supplies, Hospitals, Diabetes, Health Insurance, Biotechnology, Managed Care, Health, Pharmaceutical, General Health, Spend, Disease, Artemis, Attention, Research, PMPY, Korea Disease Control and Prevention Agency, American Diabetes Association, COVID, Insulin, Prediabetes, Patient, Ketoacidosis, Kidney disease, Civica, Pharmacy, Pharmaceutical industry

Diabetes costs U.S. employers approximately $245 billion a year — more than double what the entire American automotive industry is worth, according to new data announced today by Nomi Health .

Key Points: 
  • Diabetes costs U.S. employers approximately $245 billion a year — more than double what the entire American automotive industry is worth, according to new data announced today by Nomi Health .
  • As part of the Nomi Health Trends in Spend Tracker — a series using claims analysis data to call attention and action to key shifts in healthcare costs — Nomi Health analyzed nearly half a million employer health insurance claims to reveal changes in employer spend on diabetes.
  • We must turn these spend insights into meaningful action,” Nomi Health Co-founder and CEO Mark Newman said.
  • Previous Nomi Health Trends in Spend Trackers explored pediatric mental health utilization and the costs of long COVID , which outpaced diabetes in 2022 employer health care costs.

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Monday, August 15, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, T1D, Risk, Type 2 diabetes, Industry, DKA, GLOBE, CEO, Food, R, Clinical trial, Sale, VTV, Board, Diabetic ketoacidosis, General Administration of Press and Publication, Income, Marketing, Quality of life, Patient, Ketoacidosis, Therapy, American Diabetes Association, Company, Hypoglycemia, Research and development, Program, G&A, Receptor (biochemistry), Diabetes, Obesity and Metabolism, Expense, Nasdaq, Metabolism, Administration, Management, Pharmaceutical industry, G42

HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June30, 2022, and provided an update on recent corporate developments.

Key Points: 
  • HIGH POINT, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the second quarter ended June30, 2022, and provided an update on recent corporate developments.
  • On July 27, 2022, the Company appointed Paul Sekhri as President, Chief Executive Officer (CEO) effective August 1, 2022, and was confirmed as a member of the board of directors on August 9, 2022.
  • Net Loss:Net loss attributable to vTv shareholders for the three months ended June30, 2022, was $3.2 million or $0.04 per basic share.
  • Net loss attributable to vTv shareholders for the comparable period a year ago was $0.6 million or $0.01 per basic share.

vTv Therapeutics Announces Investment by CinRx Pharma

Retrieved on: 
Monday, July 25, 2022
Sale, Common, Partnership, Breakthrough therapy, Review, Interim, Insulin, Doctor of Philosophy, Harvard Medical School, LLC, G42, Investment, Diabetes, Common stock, Sumathi Best Television Current Reporting Award, Biotechnology, Food, Faculty, Pharmacology, GLOBE, Industry, Medicine, Internal medicine, SEC, Pancreatic cancer, Disease, FDA, Cardiology, Nasdaq, Therapy, Annual report, Metabolism, Kidney, Chronic obstructive pulmonary disease, Risk, Ketoacidosis, Teva Pharmaceuticals, VTV, Drug development, Yale School of Medicine, Patient, Terminology, Cystic fibrosis, Pharmaceutical industry, Medpace

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (CinPax), a subsidiary of CinRx Pharma, LLC (CinRx).

Key Points: 
  • HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (CinPax), a subsidiary of CinRx Pharma, LLC (CinRx).
  • In addition to the $10 million investment, the CinRx team brings exceptional industry experience in developing therapeutics.
  • On top of last months announcement of G42 Healthcares $25 million investment into vTv, this investment provides additional funding towards our Phase 3 clinical trials for TTP399, said Rich Nelson, Interim Chief Executive Officer of vTv.
  • Dr. Jon Isaacsohn, Chief Executive Officer of CinRx, who has been involved in the clinical development of countless therapeutics, is expected to join the vTv Board of Directors.

Readout Health Biosense device to be tested in JDRF-funded clinical trial in people with Type 1 Diabetes using SGLT inhibitors at Washington University

Retrieved on: 
Tuesday, July 12, 2022
Technology, American Diabetes Association, Clinical trial, Safety, Health, Diabetic ketoacidosis, Multimedia, Ketoacidosis, Volunteering, Washington University School of Medicine, Risk, Patient, Doctor of Philosophy, Review, George Washington University School of Medicine & Health Sciences, MD, Lists of diseases, Insulin, Heart failure, Degenerative disease, Ketone, Chronic kidney disease, T2D, Kidney disease, SGLT, FDA, Ketosis, Person, Exercise, Obesity, DKA, Efficiency, Industry, JDRF, Medical device, Pharmaceutical industry, T1D, Research, BioSense, St. Louis

ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF. The two-year grant is aimed at testing the efficacy of the Biosense® handheld breath ketone monitor in persons with type 1 diabetes (T1D) during usual care with insulin and with the addition of a sodium glucose transporter inhibitor (SGLT2i) drug. Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award, will serve as the principal investigator.

Key Points: 
  • $360,000 grant to review safety and accuracy of Biosense device aimed at DKA risk mitigation in patients using SGLTi drug class.
  • ST. LOUIS, July 12, 2022 /PRNewswire/ -- Readout Health, a medical digital health startup, announces a sponsored research agreement with Washington University School of Medicine in St. Louis that received a $360,000 research grant from JDRF.
  • Janet McGill, MD, a professor at Washington University School of Medicine and the recipient of the American Diabetes Association's 2022 Outstanding Physician Clinician award,will serve as the principal investigator.
  • Development of ketone monitoring technologies like Biosense are a critical part of the strategy to enable safe, effective use of SGLT inhibitors in type 1 diabetes."